Immunis, Inc.

Immunis, Inc.

Biotechnology Research

Irvine, California 1,272 followers

Developing innovative, stem cell-derived secretome therapies to reverse age-related diseases and immune dysfunction.

About us

Immunis Inc. is a private, clinical-stage biotechnology company developing stem cell-derived secretome therapies to address age-related diseases and immune dysfunction. The secretome is the total set of factors secreted from a cell including proteins, lipids, growth factors, cytokines, and exosomes. A well-functioning immune system is necessary for our health and secretomes can refine immune cell responses, making them a promising therapeutic for autoimmune, neurodegenerative and age-related muscle wasting diseases (sarcopenia). Our investigational secretome, IMMUNA, includes a balance of all-natural, clinical-grade factors that benefit immune system development, modulation, and health. Immunis’ published pre-clinical data in GeroScience demonstrates that IMMUNA benefits muscle regeneration, mass, and function. Immunis published additional data in Aging Cell showing that IMMUNA increases whole-body lean mass and reduces fat mass, while increasing muscle size, enhancing muscle regeneration, and improving muscle function. 100% of humans develop sarcopenia with age, which significantly impairs mobility and compromises quality of life. Preventing muscle loss and improving muscle recovery are currently unfulfilled medical needs. Immunis' first clinical trial is a Phase 1/2a study of the safety and tolerability of IMMUNA for elderly individuals who have age-related muscle atrophy. The trial is currently ongoing. Immunis was recently granted permission by the FDA to proceed with its Phase II clinical trial testing of IMMUNA in reversing sarcopenic obesity. Obesity rates have skyrocketed within the past few decades, with a heavy impact on the elderly population. Age-related obesity is strongly linked with additional health concerns including diabetes and muscle loss, which can have detrimental effects on quality of life. “Our innovative therapy shows promising results by simultaneously decreasing fat and enhancing muscle,” explains Chairman Dr. Keirstead.

Website
www.immunisbiomedical.com
Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Irvine, California
Type
Privately Held
Founded
2019
Specialties
Sarcopenia, Muscle atrophy, Metabolism, Cell therapy, Secretome, human healthspan, Muscle health, and Obesity

Locations

Employees at Immunis, Inc.

Updates

Similar pages

Funding

Immunis, Inc. 3 total rounds

Last Round

Series unknown

US$ 20.4M

See more info on crunchbase